FCCC LOGO Faculty Publications
Demetri GD , Reichardt P , Kang YK , Blay JY , Rutkowski P , Gelderblom H , Hohenberger P , Leahy M , von Mehren M , Joensuu H , Badalamenti G , Blackstein M , Le Cesne A , Schoffski P , Maki RG , Bauer S , Nguyen BB , Xu JM , Nishida T , Chung J , Kappeler C , Kuss I , Laurent D , Casali PG , Grid Study Investigators
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Lancet. 2013 Jan;381(9863) :295-302
PMID: WOS:000314021800026    PMCID: PMC 3819942   
Back to previous list
Abstract
Notes
Demetri, George D. Reichardt, Peter Kang, Yoon-Koo Blay, Jean-Yves Rutkowski, Piotr Gelderblom, Hans Hohenberger, Peter Leahy, Michael von Mehren, Margaret Joensuu, Heikki Badalamenti, Giuseppe Blackstein, Martin Le Cesne, Axel Schoffski, Patrick Maki, Robert G. Bauer, Sebastian Binh Bui Nguyen Xu, Jianming Nishida, Toshirou Chung, John Kappeler, Christian Kuss, Iris Laurent, Dirk Casali, Paolo G.